METHOTREXATE
Generic: METHOTREXATE
Alembic Pharmaceuticals Inc.Manufacturer
ORALRoute
METHOTREXATE SODIUMActive Substance
2024-06-03Original Approval
METHOTREXATE is FDA application ANDA217552, sponsored by ALEMBIC. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2021-03-15
Methotrexate Injection, USP 50 mg/2mL (25 mg/mL) 5 x 2mL Single-Dose Vials, Sterile, Rx Only, Distributed by Hospira, InCGMP Deviations: Intermittent exposure to temperature excursion during storage.
Class II2012-06-27
Methotrexate Injection, USP, 25 mg/mL, 40 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured forThe affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and
Class III2023-09-22
Methotrexate Tablets, USP, 2.5 mg, 10x10 Unit-Dose Tablets per carton, Rx only, Distributed by: West-Ward PharmaceuticalFailed Tablet/Capsule Specifications: Tablets were observed to have an unsmooth surface with two tab
Top Reported Reactions
1
DRUG INEFFECTIVE
93,085 reports
2
RHEUMATOID ARTHRITIS
42,801 reports
3
ARTHRALGIA
40,718 reports
4
OFF LABEL USE
40,573 reports
5
PAIN
39,635 reports
6
FATIGUE
33,027 reports
7
NAUSEA
28,920 reports
8
JOINT SWELLING
24,995 reports
9
DRUG INTOLERANCE
24,515 reports
10
CONDITION AGGRAVATED
23,993 reports